Pro: Third-Generation Hydroxyethyl Starch Solution Is Safe and Effective for Plasma Volume Expansion During Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 1, 2018, Pages 570-575

  McConnell, Matthew ^a,b   Baisden, Josh ^a   Duncan, Andra E ^c  

^a ALLEGHENY HEALTH NETWORK   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cardiac surgery; colloid; hydroxyethyl starch

Indexed keywords

HETASTARCH; RINGER ACETATE; TETRASPAN; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG SAFETY; FLUID THERAPY; HEART SURGERY; HUMAN; KIDNEY FAILURE; META ANALYSIS (TOPIC); NOTE; PLASMA VOLUME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL MORTALITY; SURGICAL PATIENT; MORTALITY;

CARDIAC SURGICAL PROCEDURES; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; PLASMA SUBSTITUTES; PLASMA VOLUME;

EID: 85034771699     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.08.013     Document Type: Note

References (51)

1. Raghunathan, K., Miller, T.E., Shaw, A.D., Intravenous starches: Is suspension the best solution?. Anesth Analg 119 (2014), 731–736.
2. Westphal, M., James, M.F., Kozek-Langenecker, S., et al. Hydroxyethyl starches: Different products—different effects. Anesthesiology 111 (2009), 187–202.
3. Perner, A., Haase, N., Guttormsen, A.B., et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367 (2012), 124–134.
4. Myburgh, J.A., Finfer, S., Bellomo, R., et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 (2012), 1901–1911.
5. Food and Drug Administration. FDA safety communicaton: Boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. Available at: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/ucm082785.htm. Accessed June 17, 2017.
6. Weiskopf, R.B., Equivalent efficacy of hydroxyethyl starch 130/0.4 and human serum albumin: If nothing is the same, is everything different? The importance of context in clinical trials and statistics. Anesthesiology 119 (2013), 1249–1254.
7. Dellinger, R.P., Levy, M.M., Rhodes, A., et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39 (2013), 165–228.
8. Bihari, S., Prakash, S., Bersten, A.D., Post resusicitation fluid boluses in severe sepsis or septic shock: Prevalence and efficacy (price study). Shock 40 (2013), 28–34.
9. Irwin, M.G., Gan, T.J., Volume therapy with hydroxyethyl starches: Are we throwing the anesthesia baby out with the intensive care unit bathwater?. Anesth Analg 119 (2014), 737–739.
10. Haase, N., Perner, A., Hennings, L.I., et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-analysis and trial sequential analysis. BMJ, 346, 2013, f839.
11. Patel, A., Waheed, U., Brett, S.J., Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: Systematic review and meta-analysis. Intensive Care Med 39 (2013), 811–822.
12. Perel, P., Roberts, I., Ker, K., Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev, 2013, CD000567.
13. Zarychanski, R., Abou-Setta, A.M., Turgeon, A.F., et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic review and meta-analysis. JAMA 309 (2013), 678–688.
14. Gattas, D.J., Dan, A., Myburgh, J., et al. Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: Systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39 (2013), 558–568.
15. Hu, X., Adamson, R.H., Liu, B., et al. Starling forces that oppose filtration after tissue oncotic pressure is increased. Am J Physiol Heart Circ Physiol 279 (2000), H1724–H1736.
16. Gotts, J.E., Matthay, M.A., Sepsis: Pathophysiology and clinical management. BMJ, 353, 2016, 1585.
17. Boyd, J.H., Forbes, J., Nakada, T.A., et al. Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39 (2011), 259–265.
18. Annane, D., Siami, S., Jaber, S., et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: The CRISTAL randomized trial. JAMA 310 (2013), 1809–1817.
19. Rioux, J.P., Lessard, M., De Bortoli, B., et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 37 (2009), 1293–1298.
20. Van Der Linden, P., James, M., Mythen, M., et al. Safety of modern starches used during surgery. Anesth Analg 116 (2013), 35–48.
21. Martin, C., Jacob, M., Vicaut, E., et al. Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 118 (2013), 387–394.
22. Gillies, M.A., Habicher, M., Jhanji, S., et al. Incidence of postoperative death and acute kidney injury associated with i.v. 6% hydroxyethyl starch use: Systematic review and meta-analysis. Br J Anaesth 112 (2014), 25–34.
23. Yavari, M., Becker, R.C., Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis 27 (2009), 95–104.
24. Navickis, R.J., Haynes, G.R., Wilkes, M.M., Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: A meta-analysis of randomized trials. J Thorac Cardiovasc Surg 144 (2012), 223–230.
25. Wilkes, M.M., Navickis, R.J., Sibbald, W.J., Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: A meta-analysis of postoperative bleeding. Ann Thorac Surg 72 (2001), 527–533 discussion 534.
26. Jacob, M., Fellahi, J.L., Chappell, D., et al. The impact of hydroxyethyl starches in cardiac surgery: A meta-analysis. Crit Care, 18, 2014, 656.
27. Hanart, C., Khalife, M., De Ville, A., et al. Perioperative volume replacement in children undergoing cardiac surgery: Albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 37 (2009), 696–701.
28. Raiman, M., Mitchell, C.G., Biccard, B.M., et al. Comparison of hydroxyethyl starch colloids with crystalloids for surgical patients: A systematic review and meta-analysis. Eur J Anaesthesiol 33 (2016), 42–48.
29. Alavi, S.M., Ahmadi, B.B., Baharestani, B., et al. Comparison of the effects of gelatin, Ringer's solution and a modern hydroxyl ethyl starch solution after coronary artery bypass graft surgery. Cardiovasc J Afr 23 (2012), 428–431.
30. Akkucuk, F.G., Kanbak, M., Ayhan, B., et al. The effect of HES (130/0.4) usage as the priming solution on renal function in children undergoing cardiac surgery. Ren Fail 35 (2013), 210–215.
31. Gurbuz, H.A., Durukan, A.B., Salman, N., et al. Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: A randomized, prospective study. J Cardiothorac Surg, 8, 2013, 71.
32. Choi, Y.S., Shim, J.K., Hong, S.W., et al. Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiol 76 (2010), 584–591.
33. Hanart, C., Khalife, M., De Ville, A., et al. Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 37 (2009), 696–701.
34. Niemi, T., Schramko, A., Kuitunen, A., et al. Haemodynamics and acid-base equilibrium after cardiac surgery: comparison of rapidly degradable hydroxyethyl starch solutions and albumin. Scandinavian Journal of Surgery: SJS: Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society 97 (2008), 259–265.
35. Schramko, A.A., Suojaranta-Ylinen, R.T., Kuitunen, A.H., et al. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg 108 (2009), 30–36.
36. Alavi, S.M., Ahmadi, B.B., Baharestani, B., et al. Comparison of the effects of gelatin, Ringer's solution and a modern hydroxyl ethyl starch solution after coronary artery bypass graft surgery. Cardiovasc J Afr 23 (2012), 428–431.
37. Boks, R.H., Wijers, M.J., Hofland, J., et al. Low molecular starch versus gelatin plasma expander during CPB: does it make a difference?. Perfusion 22 (2007), 333–337.
38. Kimenai, D.M., Bastianen, G.W., Daane, C.R., et al. Effect of the colloids gelatin and HES 130/0.4 on blood coagulation in cardiac surgery patients: a randomized controlled trial. Perfusion 28 (2013), 512–519.
39. Mulavisala, K.P., Kulkarni, V., Mudunuri, R., et al. Hydroxyethyl starch 130/0.4 versus modified succinylated gelatin for volume expansion in pediatric cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Transfus Altern Transfus Med 12 (2012), 51–58.
40. Muralidhar, K., Garg, R., Mohanty, S., et al. Influence of colloid infusion on coagulation during off-pump coronary artery bypass grafting. Indian J. Anaesth 54 (2010), 147–153.
41. Ooi, J.S., Ramzisham, A.R., Zamrin, M.D., Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?. Asian Cardiovasc Thorac Ann 17 (2009), 368–372.
42. Schramko, A., Suojaranta-Ylinen, R., Kuitunen, A., et al. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth 104 (2010), 691–697.
43. Van der Linden PJ, De Hert SG, Deraedt D, et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 101:629-634, table of contents, 2005.
44. Vanhoonacker, J., Ongenae, M., Vanoverschelde, H., et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG. Acta Anaesthesiol Belgica 60 (2009), 91–97.
45. Yap, W.W., Young, D., Pathi, V., Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass–a randomised controlled trial. Perfusion 22 (2007), 57–61.
46. Akkucuk, F.G., Kanbak, M., Ayhan, B., et al. The effect of HES (130/0.4) usage as the priming solution on renal function in children undergoing cardiac surgery. Ren Fail 35 (2013), 210–215.
47. Chakravarthy, M., Muniraj, G., Patil, S., et al. A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery. Ann Card Anaesth 15 (2012), 105–110.
48. Gurbuz, H.A., Durukan, A.B., Salman, N., et al. Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study. J Cardiothorac Surg, 8, 2013, 71.
49. Lee, J.S., Ahn, S.W., Song, J.W., et al. Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. Circ J 75 (2011), 2397–2402.
50. Shahbazi, S., Zeighami, D., Allahyary, E., et al. Effect of colloid versus crystalloid administration of cardiopulmonary bypass prime solution on tissue and organ perfusion. Int Cardiovasc Res J 5 (2011), 24–31.
51. Tiryakioglu, O., Yildiz, G., Vural, H., et al. Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg, 3, 2008, 45.